TBP:CC - Tetra Bio-Pharma Receives Funding from the Government of Canada for ARDS-003
(TheNewswire)
-
The Company is receiving up to$150,000 in funding from the National Research Council of CanadaIndustrial Research Assistance Program (NRC IRAP) to support the development of its noveloral therapeutic for systemic hyperinflammation.
MONTREAL, QUEBEC – TheNewswire- March 3, 2023 - Tetra Bio-Pharma Inc.("Tetra" or the "Company") (TSX:TBP) (OTC:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery anddevelopment is excited to announce it is receiving up to$150,000 in funding from the National Research Council of CanadaIndustrial Research Assistance Program (NRC IRAP) to support aresearch and development project to enable the development of itsARDS-003 oral formulation. Specifically, the funds will be used tooptimize the formulation and perform animal non-GLP PharmacokineticStudies.
In August 2022, Tetra responded to a “ Respiratory Disease Therapeutics ” Challenge sponsored by theNational Research Council of Canada (NRC) through the InnovativeSolutions Canada program seeking potential therapeutics to treatrespiratory diseases by targeting viral infection, replication and/oraddress associated co-morbidities. The Company was subject to severaldiligent evaluations by the NRC to validate its scientific, financial,and commercial capabilities.
Dr. Guy Chamberland, CEO and Chief Regulatory Officer at Tetra,commented, “We are grateful to receive this funding which willsupport the development of the ARDS-003 oral program by investigatingsafety, pharmacokinetics, and pharmacodynamics of novel ARDS-003 oralformulation. Eligible companies who successfully complete thisChallenge could be considered for additional funding of up to $1M.”
In addition to this funding from the Government of Canada, Tetrareceived $4.5M in support from the Government of Quebec for theclinical development of ARDS-003 in the indication of acuterespiratory distress syndrome, whether or not it is caused byCOVID-19, as well as in patients with sepsis.
A Promising Treatment
ARDS-003 is a novel First in Human (FIH) drug product containing theactive pharmaceutical agent, Onternabez, a potent and selective fullagonist of the type 2 cannabinoid receptor (CB2R), an essentialimmunomodulatory target. ARDS-003 is positioned to modulate acutesystemic inflammation and prevent sepsis, ARDS, and organ damage. While the clinical profile of ARDS arising from viral (COVID) orbacterial sepsis can vary, hyperinflammation involving a dysfunctionalimmune response is a common mediator of lung damage. Tetra'spre-clinical studies have demonstrated that ARDS-003 decreases thishyperinflammatory response and slows disease progression.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTC-Pink: TBPMF) (FRA: JAM1) is a leaderin cannabinoid-derived drug discovery and development with a FDA and aHealth Canada cleared clinical program aimed at bringing novelprescription drugs and treatments to patients and their healthcareproviders. Their evidence-based scientific approach has enabled themto develop a pipeline of cannabinoid-based drug products for a rangeof medical conditions, including pain, inflammation, and oncology.With patients at the core of what they do, Tetra Bio-Pharma is focusedon providing rigorous scientific validation and safety data requiredfor inclusion into the existing biopharma industry by regulators,physicians and insurance companies.
Connect with Tetra: Email | Website | | | Instagram
Neither the TSX Exchange nor itsRegulation Services Provider (as that term is defined in the policiesof the TSX Exchange) accepts responsibility for the adequacy oraccuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-lookinginformation. All statements, other than of historical fact, thataddress activities, events or developments that the Company believes,expects or anticipates will or may occur in the future (including,without limitation, statements regarding potential acquisitions andfinancings) are forward-looking statements. Forward-looking statementsare generally identifiable by use of the words "may","will", "should", "continue","expect", "anticipate", "estimate","believe", "intend", "plan" or"project" or the negative of these words or other variationson these words or comparable terminology. Forward-looking statementsare subject to a number of risks and uncertainties, many of which arebeyond the Company's ability to control or predict, that may cause theactual results of the Company to differ materially from thosediscussed in the forward-looking statements. Factors that could causeactual results or events to differ materially from currentexpectations include, among other things, without limitation, theinability of the Company to obtain sufficient financing to execute theCompany's business plan; competition; regulation and anticipated andunanticipated costs and delays, the success of the Company's researchand development strategies, including the success of this product orany other product, the applicability of the discoveries made therein,the successful and timely completion and uncertainties related to theregulatory process, the timing of clinical trials, the timing andoutcomes of regulatory or intellectual property decisions and otherrisks disclosed in the Company's public disclosure record on file withthe relevant securities regulatory authorities. Although the Companyhas attempted to identify important factors that could cause actualresults or events to differ materially from those described inforward-looking statements, there may be other factors that causeresults or events not to be as anticipated, estimated or intended.Readers should not place undue reliance on forward-looking statements.The forward-looking statements included in this news release are madeas of the date of this news release and the Company does not undertakean obligation to publicly update such forward-looking statements toreflect new information, subsequent events or otherwise unlessrequired by applicable securities legislation.
For further information, pleasecontact Tetra Bio-Pharma Inc.:
Ms. Natalie Leroux
Phone: + 1 (833) 977-7575
SOURCE Tetra Bio-Pharma Inc.
Copyright (c) 2023 TheNewswire - All rights reserved.